Detail akcie Aravive Rg online

Business Summary: Aravive, Inc., formerly Versartis, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapies that target survival pathways for both solid tumors, as well as hematologic malignancies. Its primary therapeutic focus is the growth arrest-specific 6 (GAS6) - AXL receptor tyrosine kinase (AXL) pathway, where AXL receptor signaling promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. It is a Fc -chimeric fusion protein designed to block the activation of the Growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. Its AXL decoy receptor is a protein based on the extracellular portion of AXL that binds its ligand GAS6, sequesters it from the native receptor and prevents AXLmediated signaling.
Financial Summary: BRIEF: For the nine months ended 30 September 2020, AraviveInc revenues decreased from $4.8M to $0K. Net lossincreased 91% to $26.5M. Revenues reflect a decrease indemand for the Company's products and services due tounfavorable market conditions. Higher net loss reflectsOther Non-operating Income/Expense decrease from $1.9M(income) to $14K (expense), Research & administrativeexpenses increase of 7% to $10.7M (expense).